Skip to content
20-F

Annual Report (Foreign)

China SXT Pharmaceuticals, Inc. SXTC

0001213900-24-068266

← back to feed
Filed
Aug 13, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 31, 2024 0 sh
Rd Expense FY 2024 · Mar 31, 2024 $184.19K
Rd Expense FY 2024 · Mar 31, 2023 $200.72K
Rd Expense FY 2024 · Mar 31, 2022 $367.01K
Revenue FY 2024 · Mar 31, 2024 $1.93M
Revenue FY 2024 · Mar 31, 2023 $1.97M
Long Term Debt FY 2024 · Mar 31, 2023 $117.86K
Short Term Debt FY 2024 · Mar 31, 2023 $167.45K
Cash And Equivalents FY 2024 · Mar 31, 2023 $17.37M
Current Liabilities FY 2024 · Mar 31, 2023 $14.5M
Total Liabilities FY 2024 · Mar 31, 2023 $14.86M
Current Assets FY 2024 · Mar 31, 2023 $19.52M
Total Assets FY 2024 · Mar 31, 2023 $29.55M
Shares Diluted restated FY 2024 · Mar 31, 2022 41.59K sh
Eps Diluted restated FY 2024 · Mar 31, 2022 −$137.92